00:55 , Mar 16, 2018 |  BioCentury  |  Emerging Company Profile

Cirius safety

Cirius Therapeutics Inc. is developing a second-generation insulin sensitizer for non-alcoholic steatohepatitis that is designed to avoid cardiovascular symptoms and edema associated with first-generation agents. Insulin-sensitizing thiazolidinediones (TZDs) including Actos pioglitazone from Takeda Pharmaceutical Co. Ltd....
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc., Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and a...
07:00 , Oct 14, 2013 |  BC Week In Review  |  Clinical News

Metabolic Solutions preclinical data

In a mouse model of PD, MSDC-0160 improved motor deficits, restored neurotransmitter levels in the striatum and protected dopaminergic neurons in the substantia nigra. Data were presented at the Grand Challenges in Parkinson's Disease meeting...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Clinical News

Mitoglitazone: Phase IIa data

A double-blind, U.S. Phase IIa trial in 29 non-diabetic patients aged 55-85 with mild AD showed that once-daily 150 mg MSDC-0160 met the primary endpoint of improving regional glucose metabolism levels in regions of the...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Mitoglitazone: Phase IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 266 Type II diabetics showed that once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing FPG from baseline to week 12...
01:34 , Jun 12, 2012 |  BC Extra  |  Clinical News

Metabolic Solutions' TZD analog meets Phase IIb diabetes endpoint

Metabolic Solutions Development Co. (Kalamazoo, Mich.) said once-daily 100 and 150 mg MSDC-0160 each met the primary endpoint of reducing fasting plasma glucose from baseline to week 12 vs. placebo in a Phase IIb trial...